Hennion & Walsh Asset Management’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.65M Buy
120,686
+29,677
+33% +$904K 0.13% 199
2026
Q1
$2.26M Buy
91,009
+19,304
+27% +$500K 0.08% 317
2025
Q4
$1.82M Buy
+71,705
New +$1.6M 0.06% 376
2023
Q4
Sell
-143,080
Closed -$5.49M 837
2023
Q3
$5.49M Sell
143,080
-28,248
-16% -$639K 0.35% 51
2023
Q2
$3.25M Sell
171,328
-56,228
-25% -$1.05M 0.19% 131
2023
Q1
$3.53M Sell
227,556
-26,080
-10% -$453K 0.22% 120
2022
Q4
$4.5M Buy
253,636
+23,961
+10% +$302K 0.28% 88
2022
Q3
$1.28M Sell
229,675
-6,322
-3% -$30.9K 0.08% 271
2022
Q2
$920K Buy
235,997
+14,861
+7% +$64.2K 0.06% 331
2022
Q1
$1.22M Buy
221,136
+60,336
+38% +$376K 0.06% 299
2021
Q4
$1.37M Buy
160,800
+94,658
+143% +$781K 0.07% 294
2021
Q3
$575K Buy
66,142
+22,642
+52% +$204K 0.03% 477
2021
Q2
$460K Buy
+43,500
New +$607K 0.02% 540

Other funds holding IMVT